Acceptance of yellow fever vaccine in the older traveller: a cohort study.
Journal
Acta bio-medica : Atenei Parmensis
ISSN: 2531-6745
Titre abrégé: Acta Biomed
Pays: Italy
ID NLM: 101295064
Informations de publication
Date de publication:
02 09 2021
02 09 2021
Historique:
received:
13
04
2021
accepted:
26
04
2021
entrez:
6
9
2021
pubmed:
7
9
2021
medline:
21
9
2021
Statut:
epublish
Résumé
Current demographic changes and improvement of quality of life of elderly population have direct consequences on international travelling. The older traveller demands for specific care and precautions to be observed, as for the yellow fever (YF) vaccination, due to the increased incidence rate of adverse events following immunization (AEFI) in people aged 60 years or over. The aim of our study was to determine the adherence to YF vaccine and travel behaviours in a sample of elderly travellers moving to YF endemic areas. Participants in this cohort study were offered YF vaccine, and informed about the increased risk of AEFIs and the unavoidable risk of acquiring YF at the destination. The research was planned on survey-based design, using pre- and post-travel questionnaires. In 2018, 239 travellers aged 60 years or older attended our travel clinic, of whom 36.8% (n = 88) planned to travel to YF endemic areas and 23.0% (n = 55) for the first time. Of these, 63.6% accepted and 36.4% rejected the vaccination, with 15 travellers moving to endemic areas without immunization, including one patient who presented contraindications to YF vaccine. The presence of more than a third of elderly travellers who travelled without vaccination is a substantial public health problem and, since the number of older travellers continues to increase, it becomes necessary to implement robust actions to improve YF vaccine advocacy and adherence.
Sections du résumé
BACKGROUND AND AIM
Current demographic changes and improvement of quality of life of elderly population have direct consequences on international travelling. The older traveller demands for specific care and precautions to be observed, as for the yellow fever (YF) vaccination, due to the increased incidence rate of adverse events following immunization (AEFI) in people aged 60 years or over. The aim of our study was to determine the adherence to YF vaccine and travel behaviours in a sample of elderly travellers moving to YF endemic areas.
METHODS
Participants in this cohort study were offered YF vaccine, and informed about the increased risk of AEFIs and the unavoidable risk of acquiring YF at the destination. The research was planned on survey-based design, using pre- and post-travel questionnaires.
RESULTS
In 2018, 239 travellers aged 60 years or older attended our travel clinic, of whom 36.8% (n = 88) planned to travel to YF endemic areas and 23.0% (n = 55) for the first time. Of these, 63.6% accepted and 36.4% rejected the vaccination, with 15 travellers moving to endemic areas without immunization, including one patient who presented contraindications to YF vaccine.
CONCLUSIONS
The presence of more than a third of elderly travellers who travelled without vaccination is a substantial public health problem and, since the number of older travellers continues to increase, it becomes necessary to implement robust actions to improve YF vaccine advocacy and adherence.
Identifiants
pubmed: 34487067
doi: 10.23750/abm.v92i4.11619
pmc: PMC8477116
doi:
Substances chimiques
Yellow Fever Vaccine
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2021098Références
J Travel Med. 2000 Jul-Aug;7(4):170-4
pubmed: 11003727
Expert Rev Vaccines. 2016 Jun;15(6):681-91
pubmed: 27087465
J Travel Med. 2004 Jan-Feb;11(1):23-6
pubmed: 14769283
BMC Public Health. 2019 Oct 28;19(1):1397
pubmed: 31660916
Trop Dis Travel Med Vaccines. 2017 Jun 13;3:10
pubmed: 28883980
Trop Dis Travel Med Vaccines. 2015 Jul 29;1:3
pubmed: 28883935
PLoS Med. 2014 May 06;11(5):e1001638
pubmed: 24800812
J Clin Virol. 2014 May;60(1):67-9
pubmed: 24594082
Can Commun Dis Rep. 2016 Dec 01;42(12):246-251
pubmed: 29769995
Am J Trop Med Hyg. 2013 May;88(5):954-961
pubmed: 23458961
Vaccine. 2017 Oct 13;35(43):5751-5752
pubmed: 28689653
J Travel Med. 2020 Sep 26;27(6):
pubmed: 31897482
Vaccine. 1994 May;12(6):542-50
pubmed: 8036829
J Travel Med. 2016 Mar 28;23(3):
pubmed: 27021495
J Travel Med. 2019 Oct 14;26(7):
pubmed: 31509199
Trop Med Int Health. 2007 Aug;12(8):990-8
pubmed: 17697094
Vaccine. 2013 Dec 2;31(49):5798-805
pubmed: 24079979
Crit Rev Clin Lab Sci. 2004;41(4):391-427
pubmed: 15487593
Travel Med Infect Dis. 2008 Sep;6(5):315-20
pubmed: 18760256
Int Marit Health. 2018;69(4):285-296
pubmed: 30589069
Malar J. 2018 Apr 2;17(1):134
pubmed: 29606127
J Travel Med. 2016 Jul 04;23(5):
pubmed: 27378369
Stat Med. 1995 Oct 15;14(19):2143-60
pubmed: 8552893
Hum Vaccin Immunother. 2013 Feb;9(2):277-82
pubmed: 23291944